Safety and efficacy of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are ineligible for autologous stem cell transplant

Trial Profile

Safety and efficacy of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are ineligible for autologous stem cell transplant

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs Brentuximab vedotin (Primary)
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Oct 2016 Data from this trial will be presented at the 10th International Symposium on Hodgkin Lymphoma (ISHL) 2016, as reported by a Takeda media release.
    • 20 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top